Selective androgen receptor modulators for the treatment of late onset male hypogonadism by Christopher C Coss, Amanda Jones, Michael L Hancock, Mitchell S Steiner, James T Dalton

Get full text

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer by Jharna Datta, Natalie Willingham, Jasmine M. Manouchehri, Patrick Schnell, Patrick Schnell, Mirisha Sheth, Joel J. David, Mahmoud Kassem, Mahmoud Kassem, Tyler A. Wilson, Tyler A. Wilson, Hanna S. Radomska, Christopher C. Coss, Christopher C. Coss, Christopher C. Coss, Chad E. Bennett, Chad E. Bennett, Chad E. Bennett, Ramesh K. Ganju, Sagar D. Sardesai, Sagar D. Sardesai, Maryam Lustberg, Bhuvaneswari Ramaswamy, Bhuvaneswari Ramaswamy, Daniel G. Stover, Daniel G. Stover, Mathew A. Cherian, Mathew A. Cherian

Get full text

Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks by Timothy H. Helms, Riley D. Mullins, Jennifer M. Thomas-Ahner, Samuel K. Kulp, Moray J. Campbell, Fabienne Lucas, Nathan Schmidt, Dana M. LeMoine, Surafel Getaneh, Zhiliang Xie, Mitch A. Phelps, Steven K. Clinton, Christopher C. Coss

Get full text

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. by Peter Y Yu, Heather L Gardner, Ryan Roberts, Hakan Cam, Seethalakshmi Hariharan, Ling Ren, Amy K LeBlanc, Hui Xiao, Jiayuh Lin, Denis C Guttridge, Xiaokui Mo, Chad E Bennett, Christopher C Coss, Yonghua Ling, Mitch A Phelps, Peter Houghton, Cheryl A London

Get full text

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor by Sophia G Liva, Yu‐Chou Tseng, Anees M Dauki, Michael G Sovic, Trang Vu, Sally E Henderson, Yi‐Chiu Kuo, Jason A Benedict, Xiaoli Zhang, Bryan C Remaily, Samuel K Kulp, Moray Campbell, Tanios Bekaii‐Saab, Mitchell A Phelps, Ching‐Shih Chen, Christopher C Coss

Get full text

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans by Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva, Min Chen, Zhiliang Xie, Justin Thomas, Bryan Remaily, Yizhen Guo, Uma L. Subrayan, Travis Costa, Timothy H. Helms, Donald J. Irby, Kyeongmin Kim, Dwight H. Owen, Samuel K. Kulp, Thomas A. Mace, Mitch A. Phelps, Christopher C. Coss

Get full text

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. by Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth

Get full text

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia by Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan C. Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, Paul Gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps

Get full text